Search
for
Sort by
Research 931–960 of 1000+
- The development of several organs and appendages is impaired in mice lacking Sp6
- Characterisation of cell cycle arrest and terminal differentiation in a maximally proliferative human epithelial tissue: Lessons from the human hair follicle matrix
- <i>Hoxc13</i> and the development of hair follicle
- Human hair follicle biomagnetism: potential biochemical correlates
- Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos
- Synthesized Ceramide Induces Growth of Dermal Papilla Cells with Potential Contribution to Hair Growth
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- The Expression of P-Responsive Genes is Related to Root Hair Growth
- Age-related downregulation of dihydrotestosterone-inactivating enzymes in human scalp sebaceous glands
- Age-related downregulation of dihydrotestosterone-inactivating enzymes in human scalp sebaceous glands
- Age-related downregulation of dihydrotestosterone-inactivating enzymes in human scalp sebaceous glands
- Correction to “MiR‐200c‐3p as a Novel Genetic Marker and Therapeutic Tool for Alopecia Areata”
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Cholesterol homeostasis in hair follicle keratinocytes is disrupted by impaired ABCA5 activity
- Possible Cellular Communication with Human Follicle Dermal Papilla Cells via Secretions from Human Hair Follicle Keratinocytes
- The Role of ATP-dependent Chromatin Remodeling in the Control of Epidermal Differentiation and Skin Stem Cell Activity
- Editors' Picks
- Local Artemis dysfunction may be one molecular mechanism for androgenetic alopecia via telomere shortening
- Influence of feed restriction on the wool proteome: A combined iTRAQ and fiber structural study
- Visible-to-Near IR Quantum Dot–Based Hypermulticolor High-Content Screening of Herbal Medicines for the Efficacy Monitoring of Hair Growth Promotion and Hair Loss Inhibition
- Keratin Gene Expression in Wool Fibre Development